ZDA
TARO

Zweig-DiMenna Associates’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Zweig-DiMenna Associates’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,800
Closed -$259K – 292
2015
Q2 		$259K Buy
1,800
+100
+6% +$14.3K 0.01% 174
2015
Q1 		$240K Buy
+1,700
New +$262K 0.01% 259
2014
Q3 		– Sell
-2,000
Closed -$280K – 326
2014
Q2 		$280K Hold
2,000
– – 0.01% 171
2014
Q1 		$222K Buy
+2,000
New +$218K 0.01% 219

Other funds holding TARO

ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
AIM
Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Zweig-DiMenna Associates's TARO Position: Q3 2015 in Review

Zweig-DiMenna Associates sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2015, closing a stake of 1,800 shares — an estimated $259K sold.

Zweig-DiMenna Associates first reported a position in TARO in Q1 2014 and held it in 4 quarters. The position peaked at $280K in Q2 2014. 121 funds tracked by Wall St. Rank hold TARO as of Q3 2015.

  • Zweig-DiMenna Associates reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2015 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 1,800 Taro Pharmaceutical Industries Ltd. shares in Q3 2015, an estimated $259K.
  • Zweig-DiMenna Associates first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2014 and held it in 4 quarters.
  • Zweig-DiMenna Associates's Taro Pharmaceutical Industries Ltd. position peaked at $280K in Q2 2014.
  • 121 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2015, filed 9 Nov 2015.